C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
CEBPA mutation
Acute myeloid leukemia
CCAAT-enhancer-binding protein α
DNA damage-inducible transcript 3
Endoplasmic reticulum stress
Unfolded protein response
Venetoclax resistance
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
30
08
2023
accepted:
04
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) with biallelic (CEBPA Human AML cell lines and murine myeloid precursor cell line 32Dcl3 cells were infected with recombinant lentiviruses to knock down CEBPA expression or over-express the two isoforms of C/EBPα. Quantitative real-time PCR and western immunoblotting were employed to determine gene expression levels. Cell apoptosis rates were assessed by flow cytometry. CFU assays were utilized to evaluate the differentiation potential of 32Dcl3 cells. Luciferase reporter analysis, ChIP-seq and ChIP-qPCR were used to validate the transcriptional regulatory ability and affinity of each C/EBPα isoform to specific sites at DDIT3 promoter. Finally, an AML xenograft model was generated to evaluate the in vivo therapeutic effect of agents. We found a negative correlation between CEBPA expression and DDIT3 levels in AML cells. After knockdown of CEBPA, DDIT3 expression was upregulated, resulting in increased apoptotic rate of AML cells induced by ER stress. Cebpa knockdown in mouse 32Dcl3 cells also led to impaired cell viability due to upregulation of Ddit3, thereby preventing leukemogenesis since their differentiation was blocked. Then we discovered that the two isoforms of C/EBPα regulate DDIT3 transcription in the opposite way. C/EBPα-p30 upregulated DDIT3 transcription when C/EBPα-p42 downregulated it instead. Both isoforms directly bound to the promoter region of DDIT3. However, C/EBPα-p30 has a unique binding site with stronger affinity than C/EBPα-p42. These findings indicated that balance of two isoforms of C/EBPα maintains protein homeostasis and surveil leukemia, and at least partially explained why AML cells with disrupted C/EBPα-p42 and/or overexpressed C/EBPα-p30 exhibit better response to chemotherapy stress. Additionally, we found that a low C/EBPα p42/p30 ratio induces resistance in AML cells to the BCL2 inhibitor venetoclax since BCL2 is a major target of DDIT3. This resistance can be overcome by combining ER stress inducers, such as tunicamycin and sorafenib in vitro and in vivo. Our results indicate that AML patients with a low C/EBPα p42/p30 ratio (e.g., CEBPA
Sections du résumé
BACKGROUND
BACKGROUND
Acute myeloid leukemia (AML) with biallelic (CEBPA
METHODS
METHODS
Human AML cell lines and murine myeloid precursor cell line 32Dcl3 cells were infected with recombinant lentiviruses to knock down CEBPA expression or over-express the two isoforms of C/EBPα. Quantitative real-time PCR and western immunoblotting were employed to determine gene expression levels. Cell apoptosis rates were assessed by flow cytometry. CFU assays were utilized to evaluate the differentiation potential of 32Dcl3 cells. Luciferase reporter analysis, ChIP-seq and ChIP-qPCR were used to validate the transcriptional regulatory ability and affinity of each C/EBPα isoform to specific sites at DDIT3 promoter. Finally, an AML xenograft model was generated to evaluate the in vivo therapeutic effect of agents.
RESULTS
RESULTS
We found a negative correlation between CEBPA expression and DDIT3 levels in AML cells. After knockdown of CEBPA, DDIT3 expression was upregulated, resulting in increased apoptotic rate of AML cells induced by ER stress. Cebpa knockdown in mouse 32Dcl3 cells also led to impaired cell viability due to upregulation of Ddit3, thereby preventing leukemogenesis since their differentiation was blocked. Then we discovered that the two isoforms of C/EBPα regulate DDIT3 transcription in the opposite way. C/EBPα-p30 upregulated DDIT3 transcription when C/EBPα-p42 downregulated it instead. Both isoforms directly bound to the promoter region of DDIT3. However, C/EBPα-p30 has a unique binding site with stronger affinity than C/EBPα-p42. These findings indicated that balance of two isoforms of C/EBPα maintains protein homeostasis and surveil leukemia, and at least partially explained why AML cells with disrupted C/EBPα-p42 and/or overexpressed C/EBPα-p30 exhibit better response to chemotherapy stress. Additionally, we found that a low C/EBPα p42/p30 ratio induces resistance in AML cells to the BCL2 inhibitor venetoclax since BCL2 is a major target of DDIT3. This resistance can be overcome by combining ER stress inducers, such as tunicamycin and sorafenib in vitro and in vivo.
CONCLUSION
CONCLUSIONS
Our results indicate that AML patients with a low C/EBPα p42/p30 ratio (e.g., CEBPA
Identifiants
pubmed: 38475919
doi: 10.1186/s13046-024-02975-3
pii: 10.1186/s13046-024-02975-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Subventions
Organisme : National Natural Science Foundation of China
ID : 82170141
Organisme : National Natural Science Foundation of China
ID : 82270221
Organisme : Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China under Grant
ID : No. LHDMZ23H160001
Organisme : Henan Province Health and Wellness Science and Technology Innovation Leader Project
ID : YXKC2021011
Organisme : Henan Provincial Medical Science and Technology Tackle Plan Project
ID : SBGJ202302041
Informations de copyright
© 2024. The Author(s).
Références
Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. Longo DL, editor. N Engl J Med. 2015;373:1136–52.
pubmed: 26376137
doi: 10.1056/NEJMra1406184
Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. JCO. 2017;35:934–46.
doi: 10.1200/JCO.2016.71.2208
DiNardo CD, Perl AE. Advances in patient care through increasingly individualized therapy. Nat Rev Clin Oncol. 2019;16:73–4.
pubmed: 30602758
pmcid: 7197511
doi: 10.1038/s41571-018-0156-2
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Avellino R, Delwel R. Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation. Blood. 2017;129:2083–91.
pubmed: 28179278
doi: 10.1182/blood-2016-09-687822
Nie Y, Su L, Li W, Gao S. Novel insights of acute myeloid leukemia with CEBPA deregulation: heterogeneity dissection and re-stratification. Crit Rev Oncol Hematol. 2021;163:103379.
pubmed: 34087345
doi: 10.1016/j.critrevonc.2021.103379
Calkhoven CF, Müller C, Leutz A. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev. 2000;14:1920–32.
pubmed: 10921906
pmcid: 316813
doi: 10.1101/gad.14.15.1920
Lin FT, MacDougald OA, Diehl AM, Lane MD. A 30-kDa alternative translation product of the CCAAT/ENHANCER binding protein alpha message: transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci U S A. 1993;90:9606–10.
pubmed: 8415748
pmcid: 47618
doi: 10.1073/pnas.90.20.9606
Lincoln AJ, Monczak Y, Williams SC, Johnson PF. Inhibition of CCAAT/ENHANCER-binding protein alpha and beta translation by upstream open reading frames. J Biol Chem. 1998;273:9552–60.
pubmed: 9545285
doi: 10.1074/jbc.273.16.9552
El-Sharkawi D, Sproul D, Allen CG, Feber A, Wright M, Hills RK, et al. Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment. Haematologica. 2018;103:91–100.
pubmed: 29025912
pmcid: 5777194
doi: 10.3324/haematol.2017.173096
Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, van Putten WLJ, Valk PJM, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113:3088–91.
pubmed: 19171880
pmcid: 2662648
doi: 10.1182/blood-2008-09-179895
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
pubmed: 35797463
doi: 10.1182/blood.2022016867
Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139:87–103.
pubmed: 34320176
doi: 10.1182/blood.2020009680
Féral K, Jaud M, Philippe C, Di Bella D, Pyronnet S, Rouault-Pierre K, et al. ER stress and unfolded protein response in leukemia: friend, foe, or both? Biomolecules. 2021;11:199.
pubmed: 33573353
pmcid: 7911881
doi: 10.3390/biom11020199
Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173–94.
pubmed: 25387057
doi: 10.1146/annurev-pathol-012513-104649
Liu L, Zhao M, Jin X, Ney G, Yang KB, Peng F, et al. Adaptive endoplasmic reticulum stress signalling via IRE1α-XBP1 preserves self-renewal of haematopoietic and pre-leukaemic stem cells. Nat Cell Biol. 2019;21:328–37.
pubmed: 30778220
pmcid: 6745703
doi: 10.1038/s41556-019-0285-6
Masciarelli S, Capuano E, Ottone T, Divona M, Lavorgna S, Liccardo F, et al. Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. Blood Adv. 2019;3:4155–60.
pubmed: 31834935
pmcid: 6929380
doi: 10.1182/bloodadvances.2019000540
Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11:381–9.
pubmed: 14685163
doi: 10.1038/sj.cdd.4401373
Parkin SE, Baer M, Copeland TD, Schwartz RC, Johnson PF. Regulation of CCAAT/ENHANCER-binding protein (C/EBP) activator proteins by heterodimerization with C/EBPgamma (IG/EBP). J Biol Chem. 2002;277:23563–72.
pubmed: 11980905
doi: 10.1074/jbc.M202184200
Cooper C, Henderson A, Artandi S, Avitahl N, Calame K. IG/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res. 1995;23:4371–7.
pubmed: 7501458
pmcid: 307392
doi: 10.1093/nar/23.21.4371
Alberich-Jordà M, Wouters B, Balastik M, Shapiro-Koss C, Zhang H, Di Ruscio A, et al. C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. J Clin Invest. 2012;122:4490–504.
pubmed: 23160200
pmcid: 3533560
doi: 10.1172/JCI65102
Liu M, Du M, Yu J, Qian Z, Gao Y, Pan W, et al. CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition. Oncoimmunology. 2022;11:2016158.
pubmed: 35003895
pmcid: 8741297
doi: 10.1080/2162402X.2021.2016158
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Wu J, Chen S, Liu H, Zhang Z, Ni Z, Chen J, et al. Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation. J Exp Clin Cancer Res. 2018;37:272.
pubmed: 30413206
pmcid: 6230241
doi: 10.1186/s13046-018-0935-8
Pulikkan JA, Tenen DG, Behre G. C/EBPα deregulation as a paradigm for leukemogenesis. Leukemia. 2017;31:2279–85.
pubmed: 28720765
pmcid: 8197657
doi: 10.1038/leu.2017.229
Heyes E, Schmidt L, Manhart G, Eder T, Proietti L, Grebien F. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML. Leukemia. 2021;35:2526–38.
pubmed: 33623142
pmcid: 7611617
doi: 10.1038/s41375-021-01169-6
Hughes JM, Legnini I, Salvatori B, Masciarelli S, Marchioni M, Fazi F, et al. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 2015;6:18534–44.
pubmed: 26053097
pmcid: 4621908
doi: 10.18632/oncotarget.4069
Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, et al. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Sci Adv. 2019;5:eaaw4304.
pubmed: 31309149
pmcid: 6620102
doi: 10.1126/sciadv.aaw4304
Sullivan GP, Flanagan L, Rodrigues DA, Ní Chonghaile T. The path to venetoclax resistance is paved with mutations, metabolism, and more. Sci Transl Med. 2022;14:eabo6891.
pubmed: 36475901
doi: 10.1126/scitranslmed.abo6891
Holz MS, Janning A, Renné C, Gattenlöhner S, Spieker T, Bräuninger A. Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines. Mol Cancer Ther. 2013;12:173–83.
pubmed: 23243060
doi: 10.1158/1535-7163.MCT-12-0532
Shi Y-H, Ding Z-B, Zhou J, Hui B, Shi G-M, Ke A-W, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy. 2011;7:1159–72.
pubmed: 21691147
doi: 10.4161/auto.7.10.16818
Wang X, Hu R, Song Z, Zhao H, Pan Z, Feng Y, et al. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. Cancer Lett. 2022;547:215880.
pubmed: 35981569
doi: 10.1016/j.canlet.2022.215880
Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27:405–19.
pubmed: 31907390
pmcid: 7206148
doi: 10.1038/s41418-019-0486-3
Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020;11:556.
pubmed: 32699213
pmcid: 7376237
doi: 10.1038/s41419-020-02760-y
Tolomeo M, Grimaudo S. The, “Janus” role of C/EBPs family members in cancer progression. Int J Mol Sci. 2020;21:4308.
pubmed: 32560326
pmcid: 7352866
doi: 10.3390/ijms21124308
Ohlsson E, Schuster MB, Hasemann M, Porse BT. The multifaceted functions of C/EBPα in normal and malignant haematopoiesis. Leukemia. 2016;30:767–75.
pubmed: 26601784
doi: 10.1038/leu.2015.324
van Galen P, Mbong N, Kreso A, Schoof EM, Wagenblast E, Ng SWK, et al. Integrated stress response activity Marks stem cells in Normal hematopoiesis and leukemia. Cell Rep. 2018;25:1109–1117.e5.
pubmed: 30380403
doi: 10.1016/j.celrep.2018.10.021
Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18:3066–77.
pubmed: 15601821
pmcid: 535917
doi: 10.1101/gad.1250704
van Galen P, Kreso A, Mbong N, Kent DG, Fitzmaurice T, Chambers JE, et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature. 2014;510:268–72.
pubmed: 24776803
doi: 10.1038/nature13228
Khateb A, Ronai ZA. Unfolded protein response in leukemia: from basic understanding to therapeutic opportunities. Trends Cancer. 2020;6:960–73.
pubmed: 32540455
pmcid: 7721105
doi: 10.1016/j.trecan.2020.05.012
Piwocka K, Vejda S, Cotter TG, O’Sullivan GC, McKenna SL. Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling. Blood. 2006;107:4003–10.
pubmed: 16469868
doi: 10.1182/blood-2005-04-1523
Khan MM, Nomura T, Chiba T, Tanaka K, Yoshida H, Mori K, et al. The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. J Biol Chem. 2004;279:11814–24.
pubmed: 14701861
doi: 10.1074/jbc.M312121200
Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, et al. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017;31:1196–205.
pubmed: 27840425
doi: 10.1038/leu.2016.329
Huiting LN, Samaha Y, Zhang GL, Roderick JE, Li B, Anderson NM, et al. UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response. Leukemia. 2018;32:2339–51.
pubmed: 29743725
pmcid: 6202254
doi: 10.1038/s41375-018-0141-x
Masciarelli S, Capuano E, Ottone T, Divona M, De Panfilis S, Banella C, et al. Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress. Leukemia. 2018;32:285–94.
pubmed: 28776567
doi: 10.1038/leu.2017.231
Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421–38.
pubmed: 32457508
pmcid: 8867924
doi: 10.1038/s41580-020-0250-z
Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR. Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold? Blood Rev. 2023;59:101036.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.
pubmed: 32786187
doi: 10.1056/NEJMoa2012971
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137–45.
pubmed: 32219442
pmcid: 7290090
doi: 10.1182/blood.2020004856
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536–51.
pubmed: 31974170
pmcid: 7124979
doi: 10.1158/2159-8290.CD-19-0710
Zhang H, Nakauchi Y, Köhnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826–39.
pubmed: 33123685
pmcid: 7591155
doi: 10.1038/s43018-020-0103-x
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791–803.
pubmed: 31932844
pmcid: 7068032
doi: 10.1182/blood.2019003988
Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 2012;119:6089–98.
pubmed: 22446485
pmcid: 3383017
doi: 10.1182/blood-2011-09-378141
Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res. 2019;25:6815–26.
pubmed: 31320594
pmcid: 6858954
doi: 10.1158/1078-0432.CCR-19-0832
Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106:1034–46.
pubmed: 32414851
doi: 10.3324/haematol.2019.244020
Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27:748–764.e4.
pubmed: 32822582
pmcid: 7655603
doi: 10.1016/j.stem.2020.07.021
Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D’Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176–87.
pubmed: 33884374
pmcid: 8054994
doi: 10.1038/s43018-020-00126-z
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D’Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9:910–25.
pubmed: 31048320
pmcid: 6606338
doi: 10.1158/2159-8290.CD-19-0125
Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. J Hematol Oncol. 2016;9:50.
pubmed: 27353420
pmcid: 4924270
doi: 10.1186/s13045-016-0280-3
Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566–81.
pubmed: 30185627
pmcid: 6279595
doi: 10.1158/2159-8290.CD-18-0140
Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022;107:58–76.
pubmed: 33353284
doi: 10.3324/haematol.2020.260331
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020;105:697–707.
pubmed: 31123034
pmcid: 7049339
doi: 10.3324/haematol.2018.205534